The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.

Kim, Hyung Suk

The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society. [electronic resource] - Breast cancer research and treatment Apr 2020 - 461-470 p. digital

Publication Type: Journal Article

1573-7217

10.1007/s10549-020-05550-4 doi


Adenocarcinoma, Mucinous--drug therapy
Antineoplastic Agents, Immunological--therapeutic use
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant--methods
Estrogen Receptor alpha--metabolism
Female
Humans
Middle Aged
Prognosis
Receptor, ErbB-2--antagonists & inhibitors
Receptors, Progesterone--metabolism
Republic of Korea
Societies, Medical
Survival Rate
Trastuzumab--therapeutic use